keine Finanzberatung

DVA · DaVita

Largest US dialysis clinic operator — with Fresenius a de-facto duopoly

Risiko 5/10 · MODERATE RISK · leveraged dialysis duopoly · $183.99 ▲ 1.28%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $183.99
  • Market cap $11.7B
  • P/E (ttm) 15.61
  • Div yield none
  • 52-wk range $101.00 – $247.49
  • Index rank #496 / —

Wichtigste Risiken

  • Commercial payer mix shifts toward Medicare rates (Shareholders) — HIGH
  • Debt-funded buybacks leave almost no equity cushion (Bondholders) — HIGH
  • Ballot initiatives and reimbursement politics (Shareholders) — MED
  • GLP-1s and kidney-care advances shrink the patient pool (Shareholders) — MED

Fazit

A cash-generative duopoly run hot on leverage — fine while commercial insurers keep overpaying, fragile if that subsidy is ever legislated away.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.